Dataset Information

Esmolol Use in Dual Axis Defibrillation Resistant Ventricular Fibrillation.

ABSTRACT: Cardiac arrest in an event of acute myocardial infarction most commonly results in life-threatening ventricular tachycardia or ventricular fibrillation (VF). Patients who remain in VF despite optimal epinephrine, amiodarone, and three or more attempts at 200 joules of biphasic current defibrillation are known to be in an electrical storm. Here, we describe a case of defibrillation refractory VF responding to intravenous esmolol resulting in a successful return of spontaneous circulation. Learning objective. This case reinforces the growing body of evidence supporting esmolol as a novel treatment approach for refractory VF before the cessation of resuscitative efforts.

SUBMITTER: Agrawal A

PROVIDER: S-EPMC7251428 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Esmolol Use in Dual Axis Defibrillation Resistant Ventricular Fibrillation.

Agrawal Ankit A Cardinale Maria M Frenia Douglas D Dalia Tarun T Shah Chirag C

Case reports in cardiology 20200517

Cardiac arrest in an event of acute myocardial infarction most commonly results in life-threatening ventricular tachycardia or ventricular fibrillation (VF). Patients who remain in VF despite optimal epinephrine, amiodarone, and three or more attempts at 200 joules of biphasic current defibrillation are known to be in an electrical storm. Here, we describe a case of defibrillation refractory VF responding to intravenous esmolol resulting in a successful return of spontaneous circulation. <i>Lear ...[more]

PMID: 32509354

Similar Datasets

Project description:BackgroundDespite high-quality cardiopulmonary resuscitation (CPR), early defibrillation, and antiarrhythmic medications, some patients remain in refractory ventricular fibrillation (VF) during out-of-hospital cardiac arrest. These patients have worse outcomes compared to patients who respond to initial treatment. Double sequential external defibrillation (DSED) and vector change (VC) defibrillation have been proposed as viable options for patients in refractory VF. However, the evidence supporting the use of novel defibrillation strategies is inconclusive. The objective of this study is to compare two novel therapeutic defibrillation strategies (DSED and VC) against standard defibrillation for patients with treatment refractory VF or pulseless ventricular tachycardia (pVT) during out-of-hospital cardiac arrest.Research questionAmong adult (≥ 18 years) patients presenting in refractory VF or pulseless ventricular tachycardia (pVT) during out-of-hospital cardiac arrest, does DSED or VC defibrillation result in greater rates of survival to hospital discharge compared to standard defibrillation?MethodsThis will be a three-arm, cluster randomized trial with repeated crossover conducted in six regions of Ontario, Canada (Peel, Halton, Toronto, Simcoe, London, and Ottawa), over 3 years. All adult (≥ 18 years) patients presenting in refractory VF (defined as patients presenting in VF/pVT and remaining in VF/pVT after three consecutive standard defibrillation attempts during out-of-hospital cardiac arrest of presumed cardiac etiology will be treated by one of three strategies: (1) continued resuscitation using standard defibrillation, (2) resuscitation involving DSED, or (3) resuscitation involving VC (change of defibrillation pads from anterior-lateral to anterior-posterior pad position) defibrillation. The primary outcome will be survival to hospital discharge. Secondary outcomes will include return of spontaneous circulation (ROSC), VF termination after the first interventional shock, VF termination inclusive of all interventional shocks, and number of defibrillation attempts to obtain ROSC. We will also perform an a priori subgroup analysis comparing rates of survival for those who receive "early DSED," or first DSED shock is shock 4-6, to those who receive "late DSED," or first DSED shock is shock 7 or later.DiscussionA well-designed randomized controlled trial employing a standardized approach to alternative defibrillation strategies early in the treatment of refractory VF is urgently required to determine if the treatments of DSED or VC defibrillation impact clinical outcomes.Trial registrationClinicalTrials.gov NCT04080986 . Registered on 6 September 2019.

Project description:BackgroundMeasures of the ventricular fibrillation (VF) waveform may enable better allocation of cardiac arrest treatment by discriminating which patients should receive immediate defibrillation versus alternate therapies such as CPR. We derive a new measure based on the 'roughness' of the VF waveform, the Logarithm of the Absolute Correlations (LAC), and assess and contrast how well the LAC and the previously published scaling exponent (ScE) predict the duration of VF and the likelihood of return of spontaneous circulation (ROSC) under both optimal experimental and commercial-defibrillator sampling conditions.Methods and resultsWe derived the LAC and ScE from two different populations--an animal study of 44 swine and a retrospective human sample of 158 out-of-hospital VF arrests treated with a commercial defibrillator. In the animal study, the LAC and ScE were calculated on 5s epochs of VF recorded at 1000 samples/s and then down sampled to 125 samples/s. In the human study, the LAC and ScE were calculated using 6s epochs recorded at 200 samples/s that occurred immediately prior to the initial shock. We compared the LAC and ScE measures using the Spearman correlation coefficients (CC) and areas under the receiver operating characteristic curve (AUC).ResultsIn the animal study, the LAC and ScE were highly correlated at 1000 sample/s (CC=0.93) but not at 125 samples/s (CC=-0.06). These correlations were reflected in how well the measures discriminated VF of < or =5 versus >5 min: AUC at 1000 samples/s was similar for LAC compared to ScE (0.71 versus 0.76). However AUC at 125 samples was greater for LAC compared to ScE (0.75 versus 0.62). In the human study, the LAC measure was a better predictor of ROSC following initial defibrillation as reflected by an AUC of 0.77 for LAC compared to 0.57 for ScE.ConclusionsThe LAC is an improvement over the ScE because the LAC retains its prognostic characteristics at lower ECG sampling rates typical of current clinical defibrillators. Hence, the LAC may have a role in better allocating treatment in resuscitation of VF cardiac arrest.

Dataset Information

Esmolol Use in Dual Axis Defibrillation Resistant Ventricular Fibrillation.

Publications

Esmolol Use in Dual Axis Defibrillation Resistant Ventricular Fibrillation.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets